MXC

Mgc Pharmaceuticals Limited

0.355
-0.03 (-7.79%)
Share Name Share Symbol Market Stock Type
Mgc Pharmaceuticals Limited MXC London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.03 -7.79% 0.355 14:35:24
Open Price Low Price High Price Close Price Previous Close
0.385 0.355 0.385 0.355 0.385
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Mgc Pharmaceuticals MXC Dividends History

No dividends issued between 07 Jun 2013 and 07 Jun 2023

Top Dividend Posts

Top Posts
Posted at 06/6/2023 22:20 by incoherent deplorable
Why did I get three thumbs down for reporting three big sells of 768K each? I merely posted that it's usually forward selling, perhaps it's not, but it's bit strange. Only an II can sell blocks simultaneously; the big trades are truncated in small chunks.

It can't be buys if the trades are below the bid price.

So the patients got experimental medication for free, according to the RNS.

I am wondering, does the doctor gets paid for a referral (retainers)? I have read somewhere doctors do get inducement for referring drugs. Is this true?

Does anyone know how much MXC is paying the docs?

Let's see how this will pan out.

Posted at 31/5/2023 10:25 by the mugger
As clockwork, rns 2-3 weeks before the next Mercer conversion, expect another 2-3 irrelevant RNS.

Last funding mid April, that money would be close to running out.

13/04/2023 7:00am
UK Regulatory (RNS & others)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart

From Mar 2023 to May 2023

Click Here for more Mgc Pharmaceuticals Charts.
TIDMMXC

RNS Number : 0968W

MGC Pharmaceuticals Limited

13 April 2023

MGC Pharmaceuticals Ltd.

Fundraise closed raising up to a total of

GBP2,090,890 (A$3,824,424)

13 April 2023

ASX, LSE: MXC

Posted at 12/4/2023 07:25 by heatseek77
Mgc Pharmaceuticals Share News - MXC
Current Price
0.435p

0.00 0.0%
Bid Price Offer Price
0.42 0.45
High Price Low Price Open Price
Shares Traded Last Trade Market Cap (m)
0.00 01:00:00 13
MGC Pharmaceuticals Limited CannEpil(R) available by Named Patient Request in UK
Intraday Mgc Pharmaceuticals Chart
Intraday Mgc Pharmaceuticals Chart
11/04/2023 7:00am
UK Regulatory (RNS & others)

TIDMMXC

RNS Number : 7816V

MGC Pharmaceuticals Limited

11 April 2023

MGC Pharmaceuticals Ltd.

CannEpil(R) now available by Named Patient Request in UK

11 April 2023

ASX, LSE: MXC

Highlights:

-- CannEpil(R) , MGC Pharma's Investigational Medicinal Product ("IMP") is now available in the United Kingdom by Named Patient Request to be prescribed by doctors on The General Medical Council ("GMC") specialist register across the UK.

-- The products will be supplied in order to meet the needs of an individual patients where an unmet medical need exists .

-- The availability via Named Patient Request follows the announcement [1] that MGC Pharma is providing CannEpil(R) to an observational trial supported by the I am Billy Foundation.

-- CannEpil(R) is in the process of a clinical development programme for patients suffering from Refractory (or Drug-Resistant) Epilepsy.

Posted at 22/3/2023 10:01 by the mugger
Funding


01/03/2023 7:02am
UK Regulatory (RNS & others)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart

From Feb 2023 to Mar 2023

Click Here for more Mgc Pharmaceuticals Charts.
TIDMMXC

RNS Number : 4761R

MGC Pharmaceuticals Limited

01 March 2023

MGC Pharmaceuticals Ltd.

Appointment of UK Lead Broker and Change of Company Secretary

01 March 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to announce the appointment of UK based Peterhouse Capital as the Company's lead broker on the LSE, with immediate effect, replacing Turner Pope. This appointment is part of the Company's UK focused corporate strategy with respect to future equity capital market financings and corporate opportunities.



MGC Pharma's non-executive chairman, Mr Brett Mitchell, commented "The board is very pleased to welcome the appointment of Peterhouse Capital as lead broker for the LSE to play a key role in the company's future funding strategies and corporate opportunities. In addition, we would also like to thank Mr David Lim for his dedication and commitment to the Company, and the board wishes him every success with his next venture."

--Ends--

Posted at 22/3/2023 09:08 by the mugger
Beware forward selling. Look at the many previous rns, another one is due in 2 weeks



MGC Pharmaceuticals Limited US$10m Financing Agreement with Mercer Street
29/07/2022 7:00am
UK Regulatory (RNS & others)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart

From Mar 2022 to Mar 2023

Click Here for more Mgc Pharmaceuticals Charts.
TIDMMXC

RNS Number : 2251U

MGC Pharmaceuticals Limited

29 July 2022

MGC Pharmaceuticals Ltd.

New US$10m Financing Agreement signed with US-based Strategic Fund and Largest Shareholder, Mercer Street Capital

29 July 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce that it has entered into a new convertible securities financing agreement (Financing Agreement) with Mercer Street Global Opportunity Fund, LLC, a fund managed by Mercer Street Capital Partners, LLC, a United States-based institutional fund manager (together, "Mercer") and MGC Pharma's largest shareholder, to provide the Company with a substantial funding facility of up to a total of US$10m. This fully funds the current MGC Pharma business plan and replaces the unused amount of the convertible facility announced in September 2020[1] , providing MGC with material financing facility to be drawn on as required to execute its strategy.

The first tranche of US$1.20 million will be provided to the Company upon satisfaction of the closing conditions (including lodging a cleansing statement), through the issue of 1.32M convertible notes with a face value of US$1 each to Mercer Street ( Tranche 1 Notes ).

This US$10m financing facility provides MGC Pharma with access to significant capital in order to execute its business commercialisation strategy primarily, with Sciensus Rare in the UK and EU and AMC in the USA, as well as advance the regulatory approvals for the Company's proprietary products to drive revenues, assist in the rollout of the ZAM App and provide funding for the Group's general corporate expenses. The Company will continue implement significant non revenue driving cost controls, as announced in it recent June Quarter Activities Report, within the operations including the delay of non-core clinical trials, and will look to use funding under this agreement selectively to support new growth and strategic initiatives.

Key Terms

The key terms of the Financing Agreement are set out below:

-- Convertible Securities facility of up to $US10m in total.
-- The initial tranche of convertible securities issued will provide funding of US$1.2m to MGC Pharma. In addition, the company will issue 21,511,545 fully paid ordinary shares to Mercer in consideration for the provision of funding. Both issues will be made utilising MGC Pharma's existing capacity.

-- Subsequent tranches of funding are available up to a value of US$8.8m within 18 months of execution of the agreement, with access to the additional funding subject to normal conditions precedent for a facility of this nature including MGC Pharma having sufficient capacity under Chapter 7 of the Listing Rules to issue the convertible notes or shareholder approval being obtained.

-- For each US$1.00 of funding provided to MGC Pharma, the Company will issue Mercer Convertible Securities to the value of US$1.10.

-- The value of outstanding Convertible Securities held by Mercer can:

Posted at 06/3/2023 23:35 by looneytune
More good news:-

7 March 2023 ASX Code: MXC LSE Code: MXC
Completion of CimetrATM Mechanism of Action study
Key Highlights:
• •

• •
TM’s ability
MGC Pharma has completed an in-vitro pre-clinical study on CimetrATM’s mechanism of
action (MoA)
The study, which was carried out at the GLP-Certified Science in Action Lab, in Ness Ziona,
Israel, examined the mechanism underlying the CimetrATM-mediated anti-inflammatory
effect on human Peripheral Blood Mononuclear Cells (PBMC)
The study demonstrated the inhibitory effect of CimetrATM on the mRNA expression and,
as a result, on the secretion of IL-32 proteins and the subsequent suppression of
inflammation and inflammatory cytokines
Additional findings show that CimetrATM increases intracellular HO-1 the antioxidant
activity in cells, protecting against oxidative stress that causes the inflammation
Further demonstrates CimetrA
to be extended into the anti-inflammatory
market
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed the pre-clinical study on CimetrATM, exploring the Mechanism of Action (MoA) of the product.
The study was conducted on human Peripheral Blood Mononuclear Cells (PBMC) crucial in the immune response, the results of which are consistent with previous reports. The administration of CimetrATM before and during Lipopolysaccharide (LPS) stimulation to produce an immune response and induce cytokine generation, resulted in a significant decrease in IL-32 mRNA expression and a resulting decrease in inflammation.
As such, we conclude that the presence of the IL-32 mRNA protein plays a critical role in the secretion of the cytokines (Figure 1), such as tumour necrosis factor-alpha (TNF-α) and IL-6 (Figure 2), that cause inflammation. Control of this protein is then the fundamental pathway to manage and reduce inflammation. The preclinical study demonstrates that the Mechanism of Action in MGC’s core development product, CimetrATM is the suppression of IL-32 protein via effect on the mRNA expression. The graph below demonstrates the decreased (up to undetectable values) IL-32A level after the treatment of the PBMC induced tissue with CimetrA in comparison with the baseline (LPS column), Placebo treatment and not treated control.

Link to article https://investi.com.au/api/announcements/mxc/f9bfd166-a6c.pdf

Posted at 01/3/2023 07:35 by looneytune
MGC Pharmaceuticals Limited Appointment of UK Lead Broker and Change of Co Sec

01/03/2023 7:02am
UK Regulatory (RNS & others)

Mgc Pharmaceuticals (LSE:MXC)
Intraday Stock Chart

Wednesday 1 March 2023
Click Here for more Mgc Pharmaceuticals Charts.
TIDMMXC

RNS Number : 4761R

MGC Pharmaceuticals Limited

01 March 2023

MGC Pharmaceuticals Ltd.

Appointment of UK Lead Broker and Change of Company Secretary

01 March 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to announce the appointment of UK based Peterhouse Capital as the Company's lead broker on the LSE, with immediate effect, replacing Turner Pope. This appointment is part of the Company's UK focused corporate strategy with respect to future equity capital market financings and corporate opportunities.

The Company also advises that Mr David Lim, MGC Pharma's Company Secretary, has retired from the position. Mr Lim has overseen the transition of the Company's corporate compliance structure to one that is significantly more organised and well positioned for the future.

Mr Lim is replaced as MGC Pharma's Company Secretary by Messrs Rowan Harland and Arron Canicais of SmallCap Corporate Pty Ltd, a Perth based corporate advisory firm, who have been appointed Joint Company Secretaries effective today.

MGC Pharma's non-executive chairman, Mr Brett Mitchell, commented "The board is very pleased to welcome the appointment of Peterhouse Capital as lead broker for the LSE to play a key role in the company's future funding strategies and corporate opportunities. In addition, we would also like to thank Mr David Lim for his dedication and commitment to the Company, and the board wishes him every success with his next venture."

--Ends--

Posted at 09/1/2023 22:00 by looneytune
News incoming:-
https://investi.com.au/api/announcements/mxc/c3c6a23e-98c.pdf

January 2023 ASX Code: MXC LSE Code: MXC
Completion of CimetrATM bioanalytics Pre-clinical Trial
Key Highlights:
• •
• • • •

MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed the pre-clinical rodent studies on CimetrATM, which are a key step in the clinical pathway prior to the planned FDA Investigational New Drug submission. Research using rodent and mammalian models are used to delineate the pharmacokinetic profile and general safety of a drug, as well as to identify toxicity patterns over a given period for the treatment before it advances to the next stage of trials, as required by US Food and Drug Administration (FDA) criteria.
The Study was undertaken to determine toxicological effects of CimetrATM over a 14-day period in rats, and was undertaken by the Smart Assays and Science in Action Laboratories in Israel, and comprised four study groups, three separate dosage groups, and one control group, with the treatment administered over a period of fourteen days, followed by a seven day review period. Blood samples for the pharmacokinetic analysis were taken on a daily basis, and histopathology tests were conducted on all organs per FDA guidelines. No anomalies were observed in the biopsies taken, nor were any clinical or behavioural adverse events recorded.
This Study is crucially important in the regulatory approval process for Investigational New Drugs (IND) approval by the FDA, and forms a key part of the metrics for the FDA's Center for Drug Evaluation and Research (CDER), the commercial and consumer watchdog, and gatekeeper to the US pharmaceutical market. There is a strict process for FDA approval: discovery, preclinical development, and clinical trial, where the boundary between preclinical development and clinical trial is sharply defined by the IND approval. Final FDA approvals will ensure that CimetrATM meets the criteria for further clinical study and
1 - 7
MGC Pharma has completed the full pre-clinical rodents study panel for CimetrATM.
The latest study, which was carried out at the Smart Assays laboratory in Israel,
included the development of bioanalytical methods and validations for further
pharmacokinetic analysis for CimetrATM.
A study on chronic toxicity in rodents was also completed by Science in Action, in Israel,
monitoring the potential development of adverse effects from using CimetrATM.
Histopathology demonstrated the full safety profile for CimetrATM across all study
dosage groups.
The study results are an important step ahead of the submission to the US Food and
Drug Administration (FDA) for Investigational New Drug (IND) approval.
No anomalies were observed in the biopsies, nor were any clinical or behavioural
adverse events recorded.
CimetrATM is MGC Pharma’s proprietary Investigational Medicinal Product which in
previous clinical trials has demonstrated anti-inflammatory and immunomodulating
properties, and is MGC’s most clinically advanced product.

development in the US, and ultimately commercial sale, therefore opening up the largest healthcare market globally to MGC Pharma.
Roby Zomer, co-founder, Managing Director and CEO of MGC Pharmaceuticals, commented: “The successful completion of this study and the excellent results attained is an important milestone moment for the Company, as we continue to progress CimetrATM along the mandated clinical pathway. The results of this study are a critical step in advancing MGC’s submission to the FDA, and for the final approval of CimetrATM as an Investigational New Drug in the US.”
A summary of results from the recently completed study can be found in Annexure A below.
About CimetrATM
CimetrATM is a nanoparticle micellar formulation based on the pharmaceutical synergetic composition consisting of Curcumin and Boswellia. In pre-clinical and clinical trials CimetrATM has demonstrated anti- inflammatory and immunomodulating effects, and can be designed for multiple therapeutic applications utilising Graft Polymer IP Ltd’s proprietary GraftBioTM Self-nano-emulsifying Drug Delivery System.
Preclinical and clinical results to date have demonstrated CimetrATM's mechanism of action as an anti- inflammatory and immunomodulatory agent which is effective in the prevention of severe inflammation by its control of increased Cytokine production resulting from an infection of the different variants of SARS-CoV-2 (the virus responsible for COVID-19); and which is the forerunner of a Cytokine Storm, which is believed to be the main reason for mortality in severe COVID-19 patients.
Authorised for release by the Board, for further information please contact:
MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au
UK Financial and Corporate Advisor
Hannam & Partners
Rupert Fane / Nilesh Patel
+44 7810 056 104
rf@hannam.partners / nilesh@hannam.partners
UK PR Advisors
Tavistock
Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd
David Lim
Company Secretary
+61 8 6382 3390 info@mgcpharma.com.au
UK Broker
Turner Pope
Andy Thacker
+44 203 657 0050 info@turnerpope.com
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on develo

Posted at 07/12/2022 06:05 by looneytune
https://investi.com.au/api/announcements/mxc/cd1347ff-cf2.pdf

7 December 2022
ASX Code: MXC
LSE Code: MXC
Completion of CimetrATM Efficacy Pre-clinical Trial
Key Highlights:
• A pre-clinical study has now been completed on a model of cytokine storm in rodents using the CimetrATM formulation, and has demonstrated an anti-inflammatory effect in three different dosages of treatments.
• The study results demonstrate CimetrATM’s effect on the anti-inflammatory and pro-inflammatory cytokines and chemokines which support the previous anti-inflammatory results of CimetrATM.
• The study results will form part of the US Food and Drug Administration (FDA) application to register CimetrATM as an Investigational New Drug (IND), and is a critical milestone in the process of drug registration.
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed pre-clinical trial testing the efficacy of the CimetrATM formulation on rodents exhibiting the cytokine storm, in order to measure the anti-inflammatory effects of three different dosages.
The trial, carried out at the GLP-certified Science in Action Laboratory in Ness Ziona, Israel, demonstrated the anti-inflammatory effect of the treatment, with the histopathology showing the reduction of lung inflammation resulting from the onset of a cytokine storm1, in comparison to the control group. This was measured through the relative protein concentration of the cellular and acellular concentrations of the lung system.
This study is the next step in the regulatory process for Investigational New Drug (IND) approval, and is one of a cohort of studies needed to evaluate safety and efficacy in preclinical and clinical models. An IND application is expected to be submitted Q1 2023 for CimetrATM, as set out in prior company releases.
Through these studies, CimetrATM has been shown to reduce the production of Interleukin 1α (IL-1α), an inflammatory cytokine responsible for activating the escalation of disease manifested in the form of severe acute or chronic inflammation. Study groups included Na├»ve, LPS, LPS solvent PBS, LPS+CimetrATM 48 μg, LPS+CimetrATM 96 μg, LPS+CimetrATM 192 μg. The graph displaying the results for each study group, control and treatment, is shown below:
1 Cytokine Storm: A severe immune overreaction in which the body releases higher than normal levels of inflammatory cytokines into
info@mgcpharma.eu | mgcpharma.co.uk 1
the blood too quickly
MGC Pharmaceuticals Ltd | 1202 Hay Street, West Perth, WA 6005 PO Box 1976, West Perth WA 6872
T: +61 8 6382 3390
- 3

Secondary test work illustrated the effect of CimetrATM on the Macrophage inflammatory protein-1 alpha (MIP-1α/CCL3), which is a chemotactic chemokine secreted by macrophages – the white blood cells that stimulate the body’s immune system. The protein performs various biological functions, such as recruiting inflammatory cells, wound healing, inhibition of stem cells, and maintaining effector immune response.
IL-17 has anti-inflammatory activity and this cytokine can suppress the development of autoimmune and inflammatory disease.
The study was completed on 55 rodents and the results presented efficacy results are statistically significant (p<0.05). This model demonstrates the anti-inflammatory mechanism of action of CimetrATM and will support the future definition of the clinical program, based on the cytokines that were affected by the drug.
Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals, commented: “The completion of this study is critical in the advancement of our submission to the FDA and for the final approval of CimetrATM as an IND in the US. There are further efficacy and safety trials to support our application, but these results are key step in the demonstration of CimetrATM as a treatment for the symptoms of the cytokine storm.”
--Ends--
2 - 3

Authorised for release by the Managing Director, for further information please contact:
MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director +61 8 6382 3390 info@mgcpharma.eu
UK Financial and Corporate Advisor
Hannam & Partners
Rupert Fane / Nilesh Patel
+44 7810 056 104
rf@hannam.partners / nilesh@hannam.partners
UK PR Advisors
Tavistock
Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd
David Lim
Company Secretary +61 8 6382 3390 info@mgcpharma.eu
UK Broker
Turner Pope
Andy Thacker
+44 203 657 0050 info@turnerpope.com
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceuticals company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company’s founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company’s EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels

Posted at 26/8/2022 08:43 by looneytune
Application for quotation of +securities
Announcement Summary
Entity name
MGC PHARMACEUTICALS LTD
Announcement Type
New announcement
Date of this announcement
Friday August 26, 2022
The +securities to be quoted are:
Other
Total number of +securities to be quoted
ASX +security code
MXC
Security description
ORDINARY FULLY PAID
Number of +securities to be quoted
20,000,000
Issue date
26/08/2022
Refer to next page for full details of the announcement
Application for quotation of +securities
1 / 6

Application for quotation of +securities
Part 1 - Entity and announcement details
1.1 Name of entity
MGC PHARMACEUTICALS LTD
We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
1.2 Registered number type
ABN
1.3 ASX issuer code
MXC
1.4 The announcement is
New announcement
1.5 Date of this announcement
26/8/2022
Registration number
30116800269
Application for quotation of +securities
2 / 6

Application for quotation of +securities
Part 2 - Type of Issue
2.1 The +securities to be quoted are:
Other
2.2 The +securities to be quoted are:
Additional +securities in a class that is already quoted on ASX ("existing class")
2.3c Have these +securities been offered under a +disclosure document or +PDS?
No
2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B
The securities have been issued in lieu of payments to employee/consultants of the Company in order for the Company to preserve working capital. Approval to issue the securities was received after business hours on the 25/8/22, as such an Appendix 3B was not deemed necessary as an Appendix 2A would be released on the same day as the Appendix 3B.
2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
Application for quotation of +securities 3 / 6

Application for quotation of +securities
Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B
Additional +securities to be quoted in an existing class
ASX +security code and description
MXC : ORDINARY FULLY PAID
Issue date
26/8/2022
Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes
Issue details
Number of +securities to be quoted
20,000,000
Are the +securities being issued for a cash consideration?
No
Please describe the consideration being provided for the +securities
The securities are being issued to employees/consultants for services rendered in lieu of cash payment.
Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted
0.019000
Any other information the entity wishes to provide about the +securities to be quoted
The purpose(s) for which the entity is issuing the securities
To pay for services rendered
Please provide additional details
The securities are being issued to employees/consultants for services rendered in lieu of cash payment.
Application for quotation of +securities 4 / 6

Application for quotation of +securities
Part 4 - Issued capital following quotation
4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)
Total number of ASX +security code and description +securities on issue
Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)
MXC : ORDINARY FULLY PAID
4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)
2,850,647,321
ASX +security code and description
MXCAF : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES
MXCAG : PERFORMANCE RIGHTS
MXCAAA : CONVERTIBLE NOTES
MXCAAC : CLASS B PERFORMANCE RIGHTS
MXCAAD : CLASS C PERFORMANCE RIGHTS
MXCAH : OPTION EXPIRING 31-MAR-2023 EX $0.026
MXCAI : OPTION EXPIRING 31-MAR-2023 EX GBP0.01475
MXCAAE : CLASS D PERFORMANCE RIGHTS
MXCAAF : CLASS E PERFORMANCE RIGHTS
Total number of +securities on issue
60,300,000
22,275,000
3,420,000
39,900,000
6,000,000
7,692,308
26,440,678
250,000
250,000
Application for quotation of +securities
5 / 6

Application for quotation of +securities
Part 5 - Other Listing Rule requirements
No
5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?
No
5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
Yes
5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
20,000,000
5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?
No
5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?
Application for quotation of +securities 6 / 6

Your Recent History
LSE
MXC
Mgc Pharma..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230607 21:37:12